- Title: Subtitle
- Long-Term Follow-Up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial
- Creators
- Stuart Seropian - Yale UniversityBoglarka Gyurkocza - Memorial Sloan Kettering Cancer CenterRajneesh Nath - Banner MD Anderson Cancer CenterHannah Choe - The Ohio State UniversityMark Litzow - Mayo ClinicCamille Abboud - Washington University in St. Louis School of MedicineNebu Koshy - Baylor University Medical CenterPatrick Stiff - Loyola University Medical CenterBenjamin Tomlinson - University Hospitals of ClevelandSunil Abhyankar - The University of Kansas Cancer CenterJames Foran - Mayo ClinicSameem Abedin - Medical College of WisconsinGeorge Chen - The University of Texas MD Anderson Cancer CenterZaid Al-Kadhimi - University of AlabamaPartow Kebriaei - The University of Texas MD Anderson Cancer CenterMitchell Sabloff - University of OttawaJohnnie Orozco - University of Washington School of MedicineKatarzyna Jamieson - University of North Carolina at Chapel HillMargarida Silverman - University of IowaKoen Van Besien - University Hospitals of ClevelandMichael Schuster - Stony Brook UniversityArjun Law - Princess Margaret Cancer CentreSebastian Mayer - Weill Cornell MedicineHillard Lazarus - Case Western Reserve UniversityJennifer Spross - Actinium PharmaceuticalsKate Li - Actinium PharmaceuticalsMadhuri Vusirikala - Actinium PharmaceuticalsBrenda Sandmaier - University of Washington School of MedicineJohn Pagel - Loxo Oncology at LillyAvinash Desai - Actinium PharmaceuticalsSergio Giralt - Memorial Sloan Kettering Cancer Center
- Resource Type
- Abstract
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.24(Supplement 1), pp.S173-S173
- Publisher
- Elsevier Inc
- DOI
- 10.1016/S2152-2650(24)00518-4
- ISSN
- 2152-2650
- Language
- English
- Date published
- 09/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984701408402771
Abstract
Long-Term Follow-Up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial
Clinical lymphoma, myeloma and leukemia, Vol.24(Supplement 1), pp.S173-S173
09/2024
DOI: 10.1016/S2152-2650(24)00518-4
Details
Metrics
2 Record Views